Search research articles
Contact Us
Filters
Showing results (81-90 of 200) with videos related to
Page
of 20
Sort By:
Journal of Medical Virology
|
November 23, 2013
Comparison of EBV DNA viral load in whole blood, plasma, B-cells and B-cell culture supernatant
David Eric Ouedraogo, Karine Bollore, Johannes Viljoen, et al.
HIV Clinical Trials
|
December 20, 2011
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results
Jacques Reynes, Adebayo Lawal, Federico Pulido, et al.
The Lancet. Infectious Diseases
|
June 9, 2014
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
Jose R Arribas, Gilles Pialoux, Joseph Gathe, et al.
The Journal of Infectious Diseases
|
February 4, 2025
γ-Aminobutyric Acid-Induced Monocytic Reactive Oxygen Species Impair CD4 Restoration in Treated Adults With HIV-1
Mehwish Younas, Sandrine Gimenez, Yea-Lih Lin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 8, 2011
HIV-1 infection impairs HSV-specific CD4(+) and CD8(+) T-cell response by reducing Th1 cytokines and CCR5 ligand secretion
Pierre-Alain Rubbo, Edouard Tuaillon, Nicolas Nagot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 1, 2005
T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists
Thierry Vincent, Pierre Portales, Vincent Baillat, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
March 31, 2005
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance
Bernard Masquelier, Edwige Pereira, Gilles Peytavin, et al.
AIDS (London, England)
|
September 10, 2002
Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy
Anne-Marie Fournier, Vincent Baillat, Catherine Alix-Panabieres, et al.
The Journal of Antimicrobial Chemotherapy
|
December 12, 2018
Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort
Lise Cuzin, Pascal Pugliese, Christine Katlama, et al.
Medical Mycology
|
October 17, 2016
Genetic diversity of the Hwp1 gene and HIS3, EF3, CDC3 microsatellites and antifungal susceptibility profiles of Candida albicans isolates from Yaoundé HIV-infected patients
Thierry Kammalac Ngouana, Pascal Drakulovski, Donika Krasteva, et al.
Page
of 20
Search research articles
Search
Showing results (81-90 of 200) with videos related to
Sort By:
Page
of 20
Journal of Medical Virology
|
November 23, 2013
Comparison of EBV DNA viral load in whole blood, plasma, B-cells and B-cell culture supernatant
David Eric Ouedraogo, Karine Bollore, Johannes Viljoen, et al.
HIV Clinical Trials
|
December 20, 2011
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results
Jacques Reynes, Adebayo Lawal, Federico Pulido, et al.
The Lancet. Infectious Diseases
|
June 9, 2014
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
Jose R Arribas, Gilles Pialoux, Joseph Gathe, et al.
The Journal of Infectious Diseases
|
February 4, 2025
γ-Aminobutyric Acid-Induced Monocytic Reactive Oxygen Species Impair CD4 Restoration in Treated Adults With HIV-1
Mehwish Younas, Sandrine Gimenez, Yea-Lih Lin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 8, 2011
HIV-1 infection impairs HSV-specific CD4(+) and CD8(+) T-cell response by reducing Th1 cytokines and CCR5 ligand secretion
Pierre-Alain Rubbo, Edouard Tuaillon, Nicolas Nagot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 1, 2005
T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists
Thierry Vincent, Pierre Portales, Vincent Baillat, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
March 31, 2005
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance
Bernard Masquelier, Edwige Pereira, Gilles Peytavin, et al.
AIDS (London, England)
|
September 10, 2002
Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy
Anne-Marie Fournier, Vincent Baillat, Catherine Alix-Panabieres, et al.
The Journal of Antimicrobial Chemotherapy
|
December 12, 2018
Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort
Lise Cuzin, Pascal Pugliese, Christine Katlama, et al.
Medical Mycology
|
October 17, 2016
Genetic diversity of the Hwp1 gene and HIS3, EF3, CDC3 microsatellites and antifungal susceptibility profiles of Candida albicans isolates from Yaoundé HIV-infected patients
Thierry Kammalac Ngouana, Pascal Drakulovski, Donika Krasteva, et al.
Page
of 20